X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs PANACEA BIOTECH - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES PANACEA BIOTECH PIRAMAL ENTERPRISES/
PANACEA BIOTECH
 
P/E (TTM) x 37.6 84.6 44.5% View Chart
P/BV x 3.7 1.9 199.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PIRAMAL ENTERPRISES   PANACEA BIOTECH
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-16
PANACEA BIOTECH
Mar-14
PIRAMAL ENTERPRISES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,065149 716.2%   
Low Rs80582 978.1%   
Sales per share (Unadj.) Rs383.084.1 455.2%  
Earnings per share (Unadj.) Rs55.1-18.3 -300.9%  
Cash flow per share (Unadj.) Rs74.1-6.7 -1,105.6%  
Dividends per share (Unadj.) Rs17.500-  
Dividend yield (eoy) %1.90-  
Book value per share (Unadj.) Rs719.983.7 860.0%  
Shares outstanding (eoy) m172.5661.25 281.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.41.4 177.8%   
Avg P/E ratio x17.0-6.3 -269.0%  
P/CF ratio (eoy) x12.6-17.2 -73.2%  
Price / Book Value ratio x1.31.4 94.1%  
Dividend payout %31.80-   
Avg Mkt Cap Rs m161,3447,074 2,280.7%   
No. of employees `0003.82.8 137.6%   
Total wages/salary Rs m16,8981,449 1,166.0%   
Avg. sales/employee Rs Th17,472.61,874.1 932.3%   
Avg. wages/employee Rs Th4,466.9527.0 847.6%   
Avg. net profit/employee Rs Th2,512.8-407.7 -616.3%   
INCOME DATA
Net Sales Rs m66,0995,154 1,282.6%  
Other income Rs m2,425100 2,429.5%   
Total revenues Rs m68,5245,254 1,304.3%   
Gross profit Rs m18,723-766 -2,443.2%  
Depreciation Rs m3,274711 460.5%   
Interest Rs m9,3881,503 624.6%   
Profit before tax Rs m8,485-2,881 -294.6%   
Minority Interest Rs m311 30.6%   
Prior Period Items Rs m1,593-6 -27,943.9%   
Extraordinary Inc (Exp) Rs m4571,771 25.8%   
Tax Rs m1,03217 6,142.3%   
Profit after tax Rs m9,506-1,121 -847.8%  
Gross profit margin %28.3-14.9 -190.5%  
Effective tax rate %12.2-0.6 -2,085.2%   
Net profit margin %14.4-21.8 -66.1%  
BALANCE SHEET DATA
Current assets Rs m47,4883,810 1,246.3%   
Current liabilities Rs m104,3628,365 1,247.6%   
Net working cap to sales %-86.0-88.4 97.4%  
Current ratio x0.50.5 99.9%  
Inventory Days Days41156 26.1%  
Debtors Days Days5167 76.1%  
Net fixed assets Rs m26,53214,480 183.2%   
Share capital Rs m34561 563.0%   
"Free" reserves Rs m114,024903 12,625.8%   
Net worth Rs m124,2215,127 2,422.8%   
Long term debt Rs m75,8125,832 1,300.0%   
Total assets Rs m308,35619,433 1,586.7%  
Interest coverage x1.9-0.9 -207.7%   
Debt to equity ratio x0.61.1 53.7%  
Sales to assets ratio x0.20.3 80.8%   
Return on assets %6.12.0 312.0%  
Return on equity %7.7-21.9 -35.0%  
Return on capital %10.03.6 273.9%  
Exports to sales %17.224.5 70.1%   
Imports to sales %6.610.2 64.8%   
Exports (fob) Rs m11,3621,264 899.0%   
Imports (cif) Rs m4,364525 831.6%   
Fx inflow Rs m14,4351,539 937.9%   
Fx outflow Rs m5,183942 550.2%   
Net fx Rs m9,253597 1,549.4%   
CASH FLOW
From Operations Rs m-67,773599 -11,310.6%  
From Investments Rs m-8,768-438 2,002.2%  
From Financial Activity Rs m76,199-303 -25,181.3%  
Net Cashflow Rs m-342-141 242.3%  

Share Holding

Indian Promoters % 52.9 74.5 71.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.6 666.7%  
FIIs % 26.6 1.3 2,046.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 23.6 69.9%  
Shareholders   93,274 10,259 909.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 18, 2017 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS